Clinical trials: SARS CoV 2 Virus
Covid-19
Clinical Performance Evaluation of SARS-CoV-2 (COVID-19) Antigen Assay in Point of Care Settings
The purpose of this study is to evaluate the performance of Freedom For All Diagnostics, Inc.'s colloidal gold immune technology SARS-CoV-2 Antigen investigational assay when compared to a high-sensitivity Emergency Use…
- Trial name
- NCT05213897
- Testing
- SARS-CoV-2 Antigen Assay
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- Freedom For All Diagnostics
COVID-19
Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)
This study is a prospective, single center, observational, cohort study of patients to (1) describe the kinetics and temporal relationship of changes in eicosanoid and cytokine mediators in patients with severe COVID-19 admitted…
- Trial name
- NCT04452942
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- EicOsis Human Health Inc.
COVID-19
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study…
- Trial name
- NCT05261139
- Testing
- nirmatrelvir, ritonavir
- Where
- 73 sites in United States, Bulgaria and 5 more
- Volunteers
- 160 people
- Sponsor
- Pfizer
COPD, Bronchiectasis
COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2
Patients with a respiratory disease are at higher risk of poor outcomes due to worsening of symptoms caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and other respiratory infections.
- Trial name
- CORVIS (NCT04858451)
- Testing
- RESP301
- Where
- 2 sites in United Kingdom
- Volunteers
- 88 people
- Sponsor
- Thirty Respiratory Limited
SARS-CoV-2 Infection, COVID-19
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
This trial consisted of three parts, Part A, Part B, and Part C, and evaluated the safety and immunogenicity of a third (booster) injection of the multivalent vaccine BNT162b2 (B.1.1.7 + B.1.617.2), and the safety and…
- Conditions
- SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)
- Trial name
- NCT05004181
- Testing
- BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7)
- Where
- 35 sites in United States, Germany and 2 more
- Volunteers
- 1,380 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS-CoV-2 Infection, COVID-19
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
This is a Phase 3, randomized, observer-blind study in healthy individuals. The primary study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate (BNT162b2): As a 30-microgram dose…
- Trial name
- NCT04713553
- Testing
- BNT162b2, BNT162b2.B.1.351
- Where
- 17 sites in United States
- Volunteers
- 1,574 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Covid19, Corona Virus Infection
Long-Term Experience and Health Effects of COVID-19
The purpose of this study is to gain on-going COVID-19 feedback/data to drive timely action locally and nationally in order to mitigate transmission.
- Conditions
- Covid19, Corona Virus Infection, Quality of Life, Risk Reduction
- Trial name
- NCT04477902
- Testing
- none - observational
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Altura
Coronavirus Disease 2019
Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
This is a randomized, multicenter, placebo-controlled, double-blind clinical study in patients hospitalized due to severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- NCT04672564
- Testing
- Carrimycin
- Where
- 17 sites in United States, Argentina and 4 more
- Volunteers
- 93 people
- Sponsor
- Shenyang Tonglian Group CO., Ltd
SARS-CoV-2 Infection
Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19
Primary: The primary objective of this study is to evaluate the efficacy of Nitric Oxide Nasal Spray combined with standard supportive care compared with standard supportive care alone in adult subjects with COVID-19 not…
- Trial name
- NCT05599919
- Testing
- Nitric Oxide
- Where
- 21 sites in India
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- Sanotize Research and Development corp.
COVID-19
A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to evaluate the efficacy, immunogenicity, reactogenicity and safety of an adjuvanted recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)…
- Trial name
- SCB-2019 (NCT04672395)
- Testing
- CpG 1018/Alum-adjuvanted SCB-2019 vaccine, SCB-2019 vaccine
- Where
- 31 sites in Belgium, Brazil and 3 more
- Volunteers
- 31,454 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
COVID-19
A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia
Evaluate the safety and effect of ORTD-1 on COVID-19 related pneumonia.
- Trial name
- NCT04708236
- Testing
- ORTD-1 low dose, ORTD-1 mid dose, ORTD-1 high dose
- Where
- United States
- Sponsor
- Oryn Therapeutics, LLC
SARS-CoV2 Infection, Influenza A
Clinical Performance Study for EDAN's COVID-19/Flu A/Flu B/RSV Test Kits on Subjects Suspected of Respiratory Infection
The primary objective of this clinical performance study is to evaluate and further validate the clinical performance of: 1. ClariLight Influenza A/B \& SARS-CoV-2 test kits and 2.
- Conditions
- SARS-CoV2 Infection, Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT06175611
- Testing
- COVID-19/Flu A/Flu B/RSV Test Kit
- Where
- 3 sites in Spain
- Volunteers
- 1,000 people
- Sponsor
- EDAN Instruments Inc.
COVID-19, Immune Response
Immunomodulatory Effect of Probiotics on the Immunogenicity of Anti-SARS-CoV-2 Vaccines
This study aims to evaluate whether oral probiotic supplementation can modulate the immune response induced by COVID-19 vaccination.
- Trial name
- NCT07610512
- Testing
- Probiotics
- Where
- Taiwan
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Grape King Bio Ltd.
COVID-19
COVID-19: A POC Test Under Research & Evaluation
Collection of nasal/nasopharyngeal/throat swabs and blood samples from patients presenting at their designated care facility displaying symptoms of COVID-19 and undergoing a SOC SARS-CoV-2 test or those who have tested positive…
- Trial name
- CAPTURE (NCT04408066)
- Testing
- Sample Collection/Performance Evaluation (A), Sample Collection/Performance Evaluation (B)
- Where
- 3 sites in United Kingdom
- Volunteers
- 523 people
- Sponsor
- LumiraDx UK Limited
COVID-19, Influenza A
Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 Assessment
A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 \& FLU A/B Test, and LumiraDx SARS-CoV-2 \& RSV Test at Point of Care Testing Sites.
- Conditions
- COVID-19, Influenza A, Influenza Type B, RSV Infection
- Trial name
- INSPIRE-2 (NCT05268939)
- Testing
- LumiraDx SARS-CoV-2 & Flu A/B test, LumiraDx SARS-CoV-2 & RSV test
- Where
- 8 sites in United States
- Volunteers
- 589 people
- Sponsor
- LumiraDx UK Limited
Patients With Moderate or Severe COVID-19
Efficacy of Amantadine Treatment in COVID-19 Patients
Demonstration of the efficacy of amantadine over placebo in the population of patients with moderate or severe COVID-19 in the initial stage of the disease treated in the hospital
- Trial name
- TITAN (NCT04952519)
- Testing
- Amantadine
- Where
- 12 sites in Poland
- Volunteers
- 193 people
- Sponsor
- Noblewell
COVID-19, COVID-19 Pandemic
Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
The purpose of this retrospective study is to evaluate the effectiveness of CPM nasal spray as part of the treatment of COVID-19 and its impact on clinical symptoms. Two cohort groups will be compared (CPM vs. standard care).
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS CoV 2 Infection
- Trial name
- ACCROS-R (NCT05520944)
- Testing
- ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
- Where
- Dominican Republic
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Dr. Ferrer BioPharma
COVID-19, Healthy
GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19)
Phase I study to assess the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine given as a booster to those previously vaccinated against SARS-CoV-2
- Trial name
- NCT05182567
- Testing
- GLS-5310 (Group 1), GLS-5310 (Group 2), GLS-5310 (Group 3)
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
COVID-19 Infection, COVID-19 Vaccine Adverse Reaction
Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)
A dose-escalation, double-blinded, randomized, placebo-controlled phase 1 study to assess the safety, reactogenicity, and immunogenicity of a SARS-CoV-2 Booster Vaccine (LEM-mR203) in healthy adults aged at 19 to 55 years
- Trial name
- NCT06032000
- Testing
- LEM-mR203
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Lemonex
Healthy Participants
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
- Trial name
- NCT07093580
- Testing
- S-892216-LAI
- Where
- 3 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Shionogi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.